Skip to main content

Fiscal Wizard · Single-issue tearsheet

DERM / Jun 22, 2026 Run #7685

DERM

Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Composite verdict

F 21.3 / 100
Bearish setup · Trend Following 5 drivers · 5 gates blocking
  • Accumulation/Distribution Line
  • Chaikin Money Flow
  • Parabolic SAR Flip
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 48th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 20Mean-reversion Neutral 41

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -88%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

34.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Asset Turnover 75
Free Cash Flow Yield 0
EV/Sales 75
Inventory Turnover 0

Technicals Bearish

8.4 / 100

Bearish setup leads (Accumulation/Distribution Line, Chaikin Money Flow, Parabolic SAR Flip); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 5
Chaikin Money Flow 11
Parabolic SAR Flip 14

Risk Gates

5 blocking 5 caution

5 guards active, 23 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for DERM.